JinXin Reproductive (01951) rose more than 4%, with the stock up 4.15% to HK$2.51 at the time of writing, and a turnover of HK$89.3858 million. The company recently disclosed that its operations in Shenzhen and the United States showed rapid growth in business metrics by the end of February 2026, extending and strengthening the performance improvement trend that began in the second half of 2025. Among these developments, the new campus of Shenzhen Zhongshan Maternity Hospital commenced trial operations on February 6, 2026. By the end of February, Shenzhen Zhongshan Maternity Hospital demonstrated robust business growth, with oocyte retrieval cycles increasing by 18% year-on-year. In the United States, driven by the implementation of the "SB729" bill, HRC Fertility reported a 38% year-on-year increase in oocyte retrieval cycles by the end of February 2026. A previous research report from PuBank International noted that the company is a leading private player in the assisted reproductive sector. With its scarce private assisted reproductive licenses and years of deep experience in the field, it is well-positioned to continue gaining market share. The report suggested that if the company's business growth in the coming quarters exceeds expectations, its stock price could see significant upward potential.